← Back to Clinical Trials
Recruiting NCT07081945

NCT07081945 hAM for Inferior RRD

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT07081945
Status Recruiting
Phase
Sponsor Eye & ENT Hospital of Fudan University
Condition Rhegmatogenous Retinal Detachment
Study Type INTERVENTIONAL
Enrollment 50 participants
Start Date 2025-08-01
Primary Completion 2026-07-31

Eligibility & Interventions

Sex All sexes
Min Age 18 Years
Max Age 70 Years
Study Type INTERVENTIONAL
Interventions
hAM

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 50 participants in total. It began in 2025-08-01 with a primary completion date of 2026-07-31.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

The objective of the study is to evaluate the efficacy of using hAM patches over the retina to seal inferior retinal breaks. The researchers will evaluate whether hAM patch-assisted vitrectomy improves surgical success rate of retinal reattachment.

Eligibility Criteria

Inclusion Criteria: 1. Subjects having given free and informed consent to take part in the study. 2. Subjects between 18 and 70 years old. 3. Subjects suffering RRD (both primary and recurrent RRDs) with at least one of these conditions: 1. inferior retinal breaks between 4- and 8-o'clock within the detached area regardless of PVR grade; 2. requiring retinotomy inferiorly between 4- and 8-o'clock (due to severe inferior PVR or inferior retinal shortening). Exclusion Criteria: 1. Subjects with RRD with only anterior retina breaks or dialysis and meet the indications for scleral buckling surgery. 2. Subjects with RRD whose retinal breaks located between the 4- and 8-o'clock positions and are not involved in the detached area. 3. Subjects with pre-existing serious eye diseases (corneal ulcers, glaucoma, uveitis, etc). 4. History of epilepsy or serious psychiatric diseases. 5. Other conditions that the researcher found improper to be included into this study.

Contact & Investigator

Central Contact

Zhongcui Sun, PhD.

✉ zhongcui.sun@aliyun.com

📞 +8621-64377134-2501

Frequently Asked Questions

Who can join the NCT07081945 clinical trial?

This trial is open to participants of all sexes, aged 18 Years or older, up to 70 Years, studying Rhegmatogenous Retinal Detachment. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT07081945 currently recruiting?

Yes, NCT07081945 is actively recruiting participants. Contact the research team at zhongcui.sun@aliyun.com for enrollment information.

Where is the NCT07081945 trial being conducted?

This trial is being conducted at Shanghai, China.

Who is sponsoring the NCT07081945 clinical trial?

NCT07081945 is sponsored by Eye & ENT Hospital of Fudan University. The trial plans to enroll 50 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology